74.07 0.00 (0.00%)
After hours: 4:41PM EDT
|Bid||70.00 x 800|
|Ask||74.19 x 800|
|Day's Range||73.60 - 75.65|
|52 Week Range||59.60 - 88.87|
|PE Ratio (TTM)||84.36|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Global Medidata CSR Activities this Summer Include All Star Code in New York, New Parklets in London, the Cures Within Reach Global Health Awards in Chicago, and More
While Medidata had a solid quarter, subscription growth was a concern for a JPMorgan analyst who downgraded the stock to neutral. Whirlpool Corporation shares saw their worst day of trading on Tuesday since 1987 as tariffs affected the company in its latest quarterly results.
NEW YORK, NY / ACCESSWIRE / July 24, 2018 / Medidata Solutions, Inc. (NASDAQ: MDSO ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 24, 2018 at 8:00 AM Eastern Time. ...
SHYFT Analytics, a Medidata Solutions (MDSO) company, announced today that Novartis has selected its Intelligent Platform for Life Sciences to support the commercialization of key therapies in Europe. Together, these solutions simplify and accelerate the aggregation, assimilation, and analysis of scores of disparate data sets that inform commercial sales and medical education programs. “Pharma companies are acutely aware of the tremendous demands on healthcare professionals’ time.
China Drug Administration and Celltrion Lead Keynote Sessions
Medidata , today announced that it will release its second quarter 2018 financial results before the open of the market on Tuesday, July 24, 2018. The Company will also hold a conference call at 8:00 a.m.
NEW YORK, June 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Health ...
With China based customers doubling in 2017, Medidata announced the appointment of Jim Xu as general manager in the market, and plans to double the size of local talent.
To make clinical research truly patient-centric, Medidata announced the launch of the Patient Burden Index on the Medidata Cloud, the Intelligent Platform for Life Sciences.
Medidata (MDSO) today announced that it has entered into a definitive agreement to acquire SHYFT Analytics, bringing the leading platform for clinical development together with the leading platform for commercial and real-world data analytics. The combined platform seamlessly delivers market-leading applications, services, and proven data science capabilities, powered by the largest global pool of research data, companies’ own CRM data, 3rd party commercial data, and real-world data sources. Pharmaceutical, biotech, and medical device companies now have an unprecedented ability to manage and optimize value across the clinical and commercial continuum.
Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Healthcare Information Services stocks: Cerner Corp. (NASDAQ: CERN), Cotiviti Holdings Inc. (NYSE: COTV), Inovalon Holdings Inc. (NASDAQ: INOV), and Medidata Solutions Inc. (NASDAQ: MDSO).
Medidata announced that Memorial Sloan Kettering Cancer Center is using Rave Omics with Biomarker Discovery for patients with pancreatic cancer, an example of the paradigm shift in clinical trials through the systematic capture of genomic data and the application of artificial intelligence algorithms.
For the second consecutive year, Medidata will be presenting its pioneering analytics innovation during the 2018 ASCO Annual Meeting. The hour-long “Industry Expert Theater” session*, Integration of Genomics Data and Analysis in Oncology Research, will occur on June 2 at 9:30 AM CDT at the Oncology Professionals Hall, McCormick Place Convention Center in Chicago.
Biotech company, PhaseBio Pharmaceuticals, has become Medidata’s (MDSO) 1,000th customer. Medidata is the first and only eClinical company to achieve this milestone. PhaseBio intends to use the Medidata Clinical Cloud® for the initial Phase I study of its newest clinical development program for treatment of an orphan cardiopulmonary disease.
Heart disease is the leading cause of death for both men and women. In partnership with the American Heart Association, Medidata (MDSO) is holding its first annual ‘Global Heart Health Awareness’ week to provide employees around the world with activities that inspire healthier living. Medidata is dedicated to supporting both its employees and the research community on the mission to eradicate heart disease.
Medidata today announced that Tarek Sherif, chairman and chief executive officer, will present at the 46th Annual J.P. Morgan Global Technology, Media and Communication Conference on Wednesday, May 16, 2018, at 3:00 p.m.
To help organizations mitigate the risk of regulatory non-approval and delays, Medidata Solutions is transforming how clinical trial data is validated prior to FDA submission with Edge Trial Assurance.
Medidata (MDSO) is pleased to announce that its director of strategic accounts and medical device/diagnostic sales, Melinda Pautsch, has been named a 2018 “Rising Star” by the Healthcare Businesswomen’s Association (HBA). In her role, Pautsch leads the team responsible for bringing the company’s transformative technologies to mid-sized biotech and medical devices and diagnostics (MD&D) organizations. Under Pautsch’s leadership, her team conducted several innovative projects, including the introduction of mobile health technology to a large device manufacturer to better track patient outcomes.
Medidata today announced that Rouven Bergmann, chief financial officer, will present at the Jefferies 2018 Global Technology Conference on Wednesday, May 9, 2018, at 2:30 p.m.
Medidata today announced that Idera Pharmaceuticals, Inc. , expanded its use of the Medidata Clinical Cloud® to automate operations, increase efficiencies, and gain better data visibility in order to accelerate their 2125 oncology development program.
Medidata is pleased to announce that its risk based monitoring solution, Edge Strategic Monitoring, won an Informa Clinical and Research Excellence Award, marking the third consecutive year the company earned this distinction.